CG Oncology (NASDAQ:CGON) Sets New 52-Week High – Here’s Why

CG Oncology, Inc. (NASDAQ:CGON) shares hit a new 52-week high on Wednesday . The stock traded as high as $79.52 and last traded at $80.1130, with a volume of 131965 shares trading hands. The stock had previously closed at $76.29.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on the company. Truist Financial upped their price target on CG Oncology from $82.00 to $85.00 and gave the stock a “buy” rating in a research report on Friday, August 7th. Wedbush boosted their target price on CG Oncology from $77.00 to $80.00 and gave the stock an “outperform” rating in a research note on Monday, May 11th. Wolfe Research initiated coverage on CG Oncology in a research report on Tuesday, May 19th. They set a “peer perform” rating on the stock. JPMorgan Chase & Co. increased their price target on CG Oncology from $91.00 to $96.00 and gave the company an “overweight” rating in a research note on Monday, May 11th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of CG Oncology in a report on Friday, July 17th. Eleven equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, CG Oncology has a consensus rating of “Moderate Buy” and a consensus target price of $83.18.

CG Oncology Stock Up 4.8%

The firm has a market capitalization of $7.09 billion, a price-to-earnings ratio of -29.75 and a beta of 0.23. The company’s 50 day moving average price is $69.99 and its 200 day moving average price is $65.07.

CG Oncology (NASDAQ:CGON) last released its earnings results on Thursday, August 6th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.66) by ($0.24). CG Oncology had a negative net margin of 3,602.68% and a negative return on equity of 25.20%. The firm had revenue of $1.16 million during the quarter, compared to analyst estimates of $0.36 million. As a group, analysts expect that CG Oncology, Inc. will post -3.25 earnings per share for the current year.

Insider Transactions at CG Oncology

In other news, Director Brian Guan-Chyun Liu bought 371,085 shares of the firm’s stock in a transaction that occurred on Thursday, June 25th. The stock was purchased at an average price of $66.87 per share, with a total value of $24,814,453.95. Following the completion of the acquisition, the director directly owned 1,886,236 shares of the company’s stock, valued at $126,132,601.32. This trade represents a 24.49% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director James Mulay sold 24,165 shares of CG Oncology stock in a transaction dated Friday, July 10th. The stock was sold at an average price of $75.16, for a total value of $1,816,241.40. Following the sale, the director directly owned 24,165 shares of the company’s stock, valued at $1,816,241.40. This trade represents a 50.00% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 38,129 shares of company stock worth $2,738,357 over the last three months. 4.80% of the stock is currently owned by insiders.

Institutional Trading of CG Oncology

Hedge funds and other institutional investors have recently made changes to their positions in the business. Universal Beteiligungs und Servicegesellschaft mbH raised its holdings in CG Oncology by 623.8% in the 4th quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 37,834 shares of the company’s stock worth $1,571,000 after purchasing an additional 32,607 shares during the period. Jennison Associates LLC acquired a new stake in CG Oncology in the fourth quarter valued at approximately $11,730,000. Pictet Asset Management Holding SA increased its position in shares of CG Oncology by 2.3% in the fourth quarter. Pictet Asset Management Holding SA now owns 1,349,527 shares of the company’s stock valued at $56,032,000 after buying an additional 30,960 shares in the last quarter. State of New Jersey Common Pension Fund D acquired a new position in CG Oncology during the fourth quarter worth $606,000. Finally, Hsbc Holdings PLC acquired a new position in shares of CG Oncology during the 1st quarter worth about $12,708,000. Institutional investors and hedge funds own 26.56% of the company’s stock.

CG Oncology Company Profile

CG Oncology, Inc (NASDAQ: CGON) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibody-based immunotherapies for the treatment of solid tumor cancers. The company leverages a platform-driven approach to identify and optimize antibody candidates that engage key immune checkpoints and co-stimulatory pathways within the tumor microenvironment. Its pipeline encompasses multiple preclinical programs alongside early-phase clinical trials designed to assess safety, dosing and preliminary anti-tumor activity.

Headquartered in South San Francisco, California, CG Oncology conducts clinical research primarily in the United States, collaborating with leading academic medical centers and contract research organizations to advance its lead candidates.